Logo image of CAPR

CAPRICOR THERAPEUTICS INC (CAPR) Stock Fundamental Analysis

NASDAQ:CAPR - Nasdaq - US14070B3096 - Common Stock - Currency: USD

11.86  -0.88 (-6.91%)

After market: 11.9 +0.04 (+0.34%)

Fundamental Rating

3

CAPR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 566 industry peers in the Biotechnology industry. While CAPR seems to be doing ok healthwise, there are quite some concerns on its profitability. CAPR is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CAPR has reported negative net income.
CAPR had a negative operating cash flow in the past year.
CAPR had negative earnings in each of the past 5 years.
CAPR had negative operating cash flow in 4 of the past 5 years.
CAPR Yearly Net Income VS EBIT VS OCF VS FCFCAPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

The Return On Assets of CAPR (-23.74%) is better than 74.20% of its industry peers.
With a decent Return On Equity value of -27.82%, CAPR is doing good in the industry, outperforming 79.51% of the companies in the same industry.
Industry RankSector Rank
ROA -23.74%
ROE -27.82%
ROIC N/A
ROA(3y)-39.87%
ROA(5y)-41.5%
ROE(3y)-124.19%
ROE(5y)-96.97%
ROIC(3y)N/A
ROIC(5y)N/A
CAPR Yearly ROA, ROE, ROICCAPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

CAPR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAPR Yearly Profit, Operating, Gross MarginsCAPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

5

2. Health

2.1 Basic Checks

CAPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
CAPR has more shares outstanding than it did 1 year ago.
CAPR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CAPR has been reduced compared to a year ago.
CAPR Yearly Shares OutstandingCAPR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CAPR Yearly Total Debt VS Total AssetsCAPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

CAPR has an Altman-Z score of 12.62. This indicates that CAPR is financially healthy and has little risk of bankruptcy at the moment.
CAPR's Altman-Z score of 12.62 is amongst the best of the industry. CAPR outperforms 90.28% of its industry peers.
CAPR has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.02, CAPR is in line with its industry, outperforming 41.17% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 12.62
ROIC/WACCN/A
WACC9.95%
CAPR Yearly LT Debt VS Equity VS FCFCAPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 7.77 indicates that CAPR has no problem at all paying its short term obligations.
The Current ratio of CAPR (7.77) is better than 73.50% of its industry peers.
A Quick Ratio of 7.77 indicates that CAPR has no problem at all paying its short term obligations.
CAPR has a better Quick ratio (7.77) than 73.67% of its industry peers.
Industry RankSector Rank
Current Ratio 7.77
Quick Ratio 7.77
CAPR Yearly Current Assets VS Current LiabilitesCAPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

CAPR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.93%.
The Revenue for CAPR has decreased by -11.58% in the past year. This is quite bad
The Revenue has been growing by 85.64% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-37.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
Revenue 1Y (TTM)-11.58%
Revenue growth 3Y352.73%
Revenue growth 5Y85.64%
Sales Q2Q%-7.92%

3.2 Future

CAPR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.01% yearly.
CAPR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 93.14% yearly.
EPS Next Y73.82%
EPS Next 2Y39.15%
EPS Next 3Y42.25%
EPS Next 5Y23.01%
Revenue Next Year132.71%
Revenue Next 2Y145.03%
Revenue Next 3Y119.11%
Revenue Next 5Y93.14%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CAPR Yearly Revenue VS EstimatesCAPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M
CAPR Yearly EPS VS EstimatesCAPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CAPR. In the last year negative earnings were reported.
Also next year CAPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CAPR Price Earnings VS Forward Price EarningsCAPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAPR Per share dataCAPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

CAPR's earnings are expected to grow with 42.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.15%
EPS Next 3Y42.25%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CAPR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAPRICOR THERAPEUTICS INC

NASDAQ:CAPR (5/2/2025, 8:00:02 PM)

After market: 11.9 +0.04 (+0.34%)

11.86

-0.88 (-6.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-19 2025-03-19/amc
Earnings (Next)05-08 2025-05-08
Inst Owners38.5%
Inst Owner Change0.44%
Ins Owners1.16%
Ins Owner Change0.31%
Market Cap541.76M
Analysts84.62
Price Target44.59 (275.97%)
Short Float %28.08%
Short Ratio7.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)18.23%
Min EPS beat(2)-3.97%
Max EPS beat(2)40.43%
EPS beat(4)2
Avg EPS beat(4)-32.02%
Min EPS beat(4)-168.17%
Max EPS beat(4)40.43%
EPS beat(8)6
Avg EPS beat(8)-1.33%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)27.11%
Min Revenue beat(2)-37.86%
Max Revenue beat(2)92.08%
Revenue beat(4)2
Avg Revenue beat(4)2.52%
Min Revenue beat(4)-50.41%
Max Revenue beat(4)92.08%
Revenue beat(8)6
Avg Revenue beat(8)94.38%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.03%
PT rev (3m)5.88%
EPS NQ rev (1m)-2.15%
EPS NQ rev (3m)12.84%
EPS NY rev (1m)67.41%
EPS NY rev (3m)69.59%
Revenue NQ rev (1m)-19.98%
Revenue NQ rev (3m)-17.38%
Revenue NY rev (1m)33.15%
Revenue NY rev (3m)33.15%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 24.33
P/FCF N/A
P/OCF N/A
P/B 3.72
P/tB 3.72
EV/EBITDA N/A
EPS(TTM)-1.2
EYN/A
EPS(NY)-0.31
Fwd EYN/A
FCF(TTM)-0.91
FCFYN/A
OCF(TTM)-0.88
OCFYN/A
SpS0.49
BVpS3.18
TBVpS3.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -23.74%
ROE -27.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.87%
ROA(5y)-41.5%
ROE(3y)-124.19%
ROE(5y)-96.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 107.99%
Cap/Sales 6.91%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.77
Quick Ratio 7.77
Altman-Z 12.62
F-Score4
WACC9.95%
ROIC/WACCN/A
Cap/Depr(3y)311.17%
Cap/Depr(5y)361.27%
Cap/Sales(3y)48.94%
Cap/Sales(5y)164.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.93%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-700%
EPS Next Y73.82%
EPS Next 2Y39.15%
EPS Next 3Y42.25%
EPS Next 5Y23.01%
Revenue 1Y (TTM)-11.58%
Revenue growth 3Y352.73%
Revenue growth 5Y85.64%
Sales Q2Q%-7.92%
Revenue Next Year132.71%
Revenue Next 2Y145.03%
Revenue Next 3Y119.11%
Revenue Next 5Y93.14%
EBIT growth 1Y-76.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.08%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-50.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.25%
OCF growth 3YN/A
OCF growth 5YN/A